Full Generic Medicine Info
Dosage/Direction for Use

Susceptible infections
Adult: Initially, 400 mg on the 1st day, followed by 200 mg daily.
Renal impairment:
CrCl (ml/min)Dosage Recommendation
<30400 mg as the loading dose, then 200 mg every 48 hr.
Hypersensitivity; lactation; pregnancy. Patients <18 yr.
Special Precautions
Impaired hepatic or renal function; G6PD deficiency; myasthenia gravis; maintain adequate fluid intake; avoid excessive alkalinity of the urine. Avoid exposure to strong sunlight/sunlamp; epilepsy; history of CNS disorders. Discontinue in case of tendon pain, inflammation or rupture. May impair ability to drive and operate machinery. High level of resistance with S. aureus infections. May prolong QT interval. Avoid usage in Methicillin-Resistant S. aureus (MRSA) infections.
Adverse Reactions
GI disturbances; CNS effects; hypersensitivity-type reactions; reversible arthralgia; hepatic effects; haematological disturbances; tachycardia; superinfection; pain and irritation at inj site; tendon damage; phloebitis and thrombophloebitis.
Drug Interactions
May inhibit hepatic metabolism and clearance of drugs metabolised in the liver e.g. theophylline and caffeine; antacids and metal cations; antineoplastics. Efficacy may be affected when used with histamine H2 antagonists.
Lab Interference
Elevated liver enzyme values.
Rufloxacin inhibits DNA gyrase which is essential in bacterial DNA reproduction. It is active against gram-positive, but particularly active against gram-negative bacteria, including salmonella, shigella, campylobacter, neisseria and pseudomonas.
Absorption: Approximately 60% of an oral dose is absorbed.
Distribution: About 60-80% bound to plasma proteins.
Excretion: Plasma half-life: about 30 hr. Occurs through renal and nonrenal mechanisms. About 21-53% excreted unchanged in urine.
CIMS Class
ATC Classification
J01MA10 - rufloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on rufloxacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in